Pharmacological targeting of circadian clock components to treat glioblastoma
Description: The circadian clock appropriately times cellular functions in the context of the twenty-four hour day while weakened circadian regulation is commonly associated with the onset and rapid progression of cancer. We propose to develop specific, non-toxic, potent drugs that activate core circadian clock regulators with the goal of using these new drugs to treat aggressive cancers including glioblastomas.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2019-09-20
End date: 2024-08-31
Investigator: SATCHIDANANDA PANDA
Institution: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 14
Funder award ID: R01CA236352
OpenAlex ID: G4063479015